ProCE Banner Activity

Characterizing and Managing T-Cell Lymphomas: An Expert’s Review of Current Clinical Practice

Clinical Thought
Read this commentary from lymphoma expert Steven M. Horwitz, MD, on the current approach for characterization and management of T-cell lymphomas using biomarkers and targeted therapies.

Released: October 14, 2021

Expiration: October 13, 2022

Share

Faculty

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Kyowa Kirin Inc

Seagen Inc.

Takeda Oncology

Faculty Disclosure

Primary Author

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from Acrotech Biopharma, C4 Therapeutics, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, SecuraBio, Shoreline Biosciences, Takeda, Trillium Therapeutics, Tubulis, and Vividion Therapeutics; and funds for research support from ADC Therapeutics, Affimed, Celgene, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, Trillium Therapeutics, and Verastem/SecuraBio.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz D. Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.